Lifesaving Lincoln Laboratory device wins 2026 Excellence in Technology Transfer Award

Innovation, military necessity, and clinical excellence often converge in the most demanding environments. Such is the origin story of AI-GUIDE, a pioneering medical device engineered to revolutionize emergency vascular access in austere and pre-hospital settings. The Federal Laboratory Consortium (FLC) has officially selected AI-GUIDE for its esteemed 2026 Excellence in Technology Transfer Award. This high honor recognizes federal laboratories and their non-federal partners that have demonstrated outstanding performance in successfully transferring federally funded research and development into the commercial marketplace, thereby benefiting the public and strengthening national security.

The development and subsequent transition of AI-GUIDE represent a masterclass in interdisciplinary collaboration. Funded primarily by the U.S. Army’s Combat Casualty Care Research Program (CCC), the device was brought to life through a powerful synergy between the engineering prowess of MIT Lincoln Laboratory and the world-class clinical expertise of Massachusetts General Hospital (MGH). Today, that innovation is transitioning from laboratory prototypes to real-world commercial production via AutonomUS Medical Technologies, Inc., a startup company specifically founded to shepherd the technology through the rigorous commercialization pipeline.

The Main Facts of the Breakthrough Innovation

At its core, AI-GUIDE is designed to solve a critical, life-threatening problem on the battlefield and in civilian emergency medicine: establishing rapid, reliable vascular access. In traditional hospital settings, trained medical professionals use standard ultrasound machines to guide needles, guidewires, and catheters into a patient’s blood vessels. However, these hospital-grade ultrasound systems are bulky, delicate, and completely impractical for combat medics operating in active theater environments.

Conversely, AI-GUIDE pairs custom-developed, highly advanced artificial intelligence software with commercial, off-the-shelf handheld ultrasound technology. This integration creates a portable, ruggedized system capable of guiding users step-by-step through the delicate process of inserting a guidewire and catheter into a patient’s blood vessel. For U.S. military medics—who are frequently tasked with keeping severely wounded soldiers alive in remote areas for days before medical evacuation becomes possible—this capability is nothing short of revolutionary. By enabling medics with minimal specialized training to perform advanced medical interventions that were previously restricted to fully equipped hospital trauma bays, AI-GUIDE dramatically elevates the baseline standard of trauma care and multiplies survival rates in the golden hour of injury.

A Rapid Chronology of Development and Commercialization

The trajectory of the AI-GUIDE project stands out within the defense and medical innovation ecosystems due to its blistering speed. Within an extraordinarily brief span of just three years, the initiative transformed from an initial operational concept proposed by the CCC into a fully functional, market-ready proof-of-concept technology backed by its own dedicated startup firm.

The chronological evolution of AI-GUIDE underscores a streamlined pathway from concept to commercial viability:

• Phase I: Conceptualization and Initial Funding (2021–2022). Recognizing an urgent operational capability gap in combat casualty care, the U.S. Army’s Combat Casualty Care Research Program initiated funding for advanced vascular access solutions. MIT Lincoln Laboratory and MGH engaged in joint research and development, combining AI engineering with clinical insights.
• Phase II: Prototyping and Clinical Validation (2022–2023). Engineers at Lincoln Laboratory developed the custom AI algorithms and integrated them with commercial handheld ultrasound hardware. Concurrently, rigorous clinical testing at MGH validated the device’s accuracy, usability, and safety profile in simulated and real-world clinical environments.
• Phase III: Spinout and Regulatory Milestones (2024). Capitalizing on the successful proof-of-concept, staff members from Lincoln Laboratory and MGH established AutonomUS Medical Technologies, Inc. to drive commercialization. With institutional support from the MIT Technology Licensing Office, the Lincoln Laboratory Technology Transfer Office, and the CCC, the startup secured a U.S. Food and Drug Administration (FDA) Breakthrough Device Designation—a specialized regulatory fast-track reserved for highly innovative technologies holding transformative lifesaving potential.
• Phase IV: Expansion and Industry Recognition (2025–2026). The project garnered substantial financial backing, including a Small Business Innovation Research (SBIR) grant from the U.S. Department of the Air Force, alongside strategic investments from private venture capital, the Department of War, and the National Institutes of Health (NIH). The device also earned a Lincoln Laboratory Best Invention Award and an R&D 100 Award before capturing the 2026 FLC Excellence in Technology Transfer Award.

Supporting Data and Ecosystem Collaboration

The success of AI-GUIDE is rooted in an institutional framework intentionally designed to eliminate traditional bureaucratic bottlenecks. Technology transfer—the process of sharing technology developed in a federal research setting with the commercial sector—is notoriously complex. Yet, the collaboration between the Defense Health Agency, MIT Lincoln Laboratory, Massachusetts General Hospital, and AutonomUS Medical Technologies demonstrated how strategic alignment can accelerate deployment timelines.

Data from the project highlights the multi-layered financial and institutional backing required to scale a medical device from defense labs to commercial markets. Beyond the foundational backing of the U.S. Army’s CCC, the infusion of capital from the U.S. Department of the Air Force’s SBIR program, the National Institutes of Health, and private investors provided AutonomUS with the runway needed to navigate FDA compliance and scale manufacturing processes. Furthermore, specialized oversight from the MIT Technology Licensing Office ensured intellectual property was appropriately managed, protecting the public investment while incentivizing private-sector risk-taking.

Official Reactions and Leadership Perspectives

The announcement of the FLC award drew widespread praise from the leadership teams spanning the defense, academic, and private sectors. Key stakeholders emphasized that the triumph of AI-GUIDE serves as a blueprint for future federal technology transfers.

Asha Rajagopal, Lincoln Laboratory’s chief technology transfer officer, highlighted the human and organizational dynamics that made the project possible. "This recognition reflects what effective technology transfer looks like—aligning the Army’s operational need with Mass General’s clinical expertise and Lincoln Laboratory’s engineering capabilities to deliver a solution with a clear path to impact. The transition to AutonomUS underscores how strong partnerships can carry a technology from development into real-world adoption," Rajagopal stated.

Echoing these sentiments, Samuel Kesner, a technical staff member in the Systems Engineering Group at Lincoln Laboratory who oversees the AI-GUIDE program, pointed to the long-term institutional legacy of the laboratory. "Lincoln Laboratory has a long record of transferring technology to industry. We are honored and proud to be recognized for the transfer of AI-GUIDE and look forward to seeing the technology commercialized and saving lives in the field. This achievement reflects the strength of the partnership among the Defense Health Agency, Lincoln Laboratory, Massachusetts General Hospital, and AutonomUS Medical Technologies," said Kesner.

The interdisciplinary team driving the initiative represents a deep bench of scientific and administrative talent. Winning team members from Lincoln Laboratory include Brian Telfer, Samuel Kesner, Lars Gjesteby, Joshua Werblin, Benjamin Roop, Alec Carruthers, and Nancy DeLosa, alongside former staff members Matt Johnson—who now serves as the vice president of engineering at AutonomUS—and Laura Brattain, currently an associate professor at the University of Central Florida. Critical administrative and legal support for the technology transfer process was provided by Asha Rajagopal, Jordan Mizerak, Melly Coronado, and Jonathan Dan.

Broader Impact and Future Implications for Trauma Care

While the initial focus of AI-GUIDE centered squarely on vascular access—a critical intervention for managing hemorrhagic shock and administering life-saving fluids or medications on the battlefield—the implications of the underlying technology extend far beyond its initial application.

The AI-GUIDE framework establishes a scalable model for embedding artificial intelligence into portable diagnostic and therapeutic tools. By democratizing complex medical procedures, such devices reduce the cognitive and technical burden on operators working under extreme psychological and physical stress. In civilian pre-hospital emergency medical services (EMS), rural healthcare facilities, and disaster-relief operations where access to specialized physicians is severely limited, tools derived from the AI-GUIDE architecture could similarly bridge the gap between patient injury and definitive hospital care.

Moreover, the research team is not resting on its laurels. Building upon the success of the vascular access module, the AI-GUIDE development team is actively expanding its technological scope. Ongoing research and development efforts are currently focused on transitioning additional advanced capabilities, including peripheral nerve block technology tailored specifically for trauma care and localized pain management in austere environments.

As AutonomUS Medical Technologies prepares to scale production and bring AI-GUIDE to wider commercial distribution, the medical and defense communities are watching closely. The convergence of military foresight, federal laboratory engineering, elite clinical research, and agile startup commercialization has yielded a tangible asset that promises to rewrite the calculus of survival for injured service members and civilians alike. Through disciplined execution and collaborative vision, AI-GUIDE has transitioned from an experimental algorithmic concept into an enduring testament to the lifesaving power of effective technology transfer.